Skip to main content
NCBI home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1985 Jun;75(6):2006–2013. doi: 10.1172/JCI111919

Metabolism of heptadecapeptide gastrin in humans studied by region-specific antisera.

S Pauwels, G J Dockray, R Walker, S Marcus
PMCID: PMC425561  PMID: 2409113

Abstract

The metabolism of synthetic human heptadecapeptide gastrin (G17) in vivo, and in serum in vitro, was studied by radioimmunoassay using region specific antisera, gel filtration, ion exchange chromatography, and high performance liquid chromatography. After infusion of G17 intravenously in normal human volunteers, COOH-terminal and NH2-terminal immunoreactive G17 fragments were generated. At a steady state, approximately 15% of COOH-terminal immunoreactivity was attributable to G14-like material and up to 25% of total NH2-terminal immunoreactivity was attributable to two NH2-terminal fragments; one had the chromatographic properties of 1-13 G17, and the other was less acidic and less hydrophobic. After stopping the infusion of G17, the latter fragments accounted for progressively greater proportions of total gastrin activity. When G17 was incubated in serum in vitro, there was time-dependent and temperature-dependent loss of immunoreactivity, and again COOH-terminal and NH2-terminal immunoreactive fragments were formed. Removal of the NH2-terminal pyroglutamic acid was probably the rate limiting step because synthetic 2-17 G17 was degraded more rapidly in serum (t1/2, 2-3 h) than G17 (t1/2, 3-5 h). EDTA blocked degradation at the COOH-terminus of both 2-17 G17 and G17 but cleavage at the NH2-terminus still occurred, giving rise to a G14-like peptide. The rate of conversion of G17 in serum was not enough to account for the production of fragments in vivo, and it is proposed that these are formed when G17 encounters enzymes on cell surfaces, perhaps during passage through the capillary circulation. The production of these fragments needs to be considered in interpreting studies of the identity, metabolism, and release of gastrin in health and disease.

Full text

PDF
2006

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Berson S. A., Yllow R. S. Nature of immunoreactive gastrin extracted from tissues of gastrointestinal tract. Gastroenterology. 1971 Feb;60(2):215–222. [PubMed] [Google Scholar]
  2. Blair E. L., Grund E. R., Lund P. K., Sanders D. J. A possible origin of circulating gastrin component IV in cats. J Physiol. 1977 Dec;273(3):561–572. doi: 10.1113/jphysiol.1977.sp012110. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Boniface J., Picone D., Schebalin M., Zfass A. M., Makhlouf G. M. Clearance rate, half-life, and secretory potency of human gastrin-17-I in different species. Gastroenterology. 1976 Aug;71(2):291–294. [PubMed] [Google Scholar]
  4. Calam J., Dockray G. J., Walker R., Tracy H. J., Owens D. Molecular forms of gastrin in peptic ulcer: comparison of serum and tissue concentrations of G17 and G34 in gastric and duodenal ulcer subjects. Eur J Clin Invest. 1980 Jun;10(3):241–247. doi: 10.1111/j.1365-2362.1980.tb00027.x. [DOI] [PubMed] [Google Scholar]
  5. Carter D. C., Taylor I. L., Elashoff J., Grossman M. I. Reappraisal of the secretory potency and disappearance rate of pure human minigastrin. Gut. 1979 Aug;20(8):705–708. doi: 10.1136/gut.20.8.705. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Dockray G. J., Gregory R. A., Tracy H. J., Zhu W. Y. Postsecretory processing of heptadecapeptide gastrin: conversion to C-terminal immunoreactive fragments in the circulation of the dog. Gastroenterology. 1982 Jul;83(1 Pt 2):224–232. [PubMed] [Google Scholar]
  7. Dockray G. J., Taylor I. L. Heptadecapeptide gastrin: measurement in blood by specific radioimmunoassay. Gastroenterology. 1976 Dec;71(6):971–977. [PubMed] [Google Scholar]
  8. Dockray G. J., Walsh J. H. Amino terminal gastrin fragment in serum of Zollinger-Ellison syndrome patients. Gastroenterology. 1975 Feb;68(2):222–230. [PubMed] [Google Scholar]
  9. Dockray G. J., Walsh J. H., Grossman M. I. Biological activity of iodinated gastrins. Biochem Biophys Res Commun. 1976 Mar 22;69(2):339–345. doi: 10.1016/0006-291x(76)90527-1. [DOI] [PubMed] [Google Scholar]
  10. GREGORY R. A., TRACY H. J. THE CONSTITUTION AND PROPERTIES OF TWO GASTRINS EXTRACTED FROM HOG ANTRAL MUCOSA. Gut. 1964 Apr;5:103–114. [PMC free article] [PubMed] [Google Scholar]
  11. Gregory R. A. The Bayliss-Starling lecture 1973. The gastrointestinal hormones: a review of recent advances. J Physiol. 1974 Aug;241(1):1–32. doi: 10.1113/jphysiol.1974.sp010637. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Gregory R. A., Tracy H. J., Harris J. I., Runswick M. J., Moore S., Kenner G. W., Ramage R. Minigastrin; corrected structure and synthesis. Hoppe Seylers Z Physiol Chem. 1979 Jan;360(1):73–80. doi: 10.1515/bchm2.1979.360.1.73. [DOI] [PubMed] [Google Scholar]
  13. Malstrom J., Stadil F., Rehfeld J. F. Gastrins in tissue. Concentration and component pattern in gastric, duodenal, and jejunal mucosa of normal human subjects and patients with duodenal ulcer. Gastroenterology. 1976 May;70(5 PT1):697–703. [PubMed] [Google Scholar]
  14. Pauwels S., Dockray G. J. Identification of NH2-terminal fragments of big gastrin in plasma. Gastroenterology. 1982 Jan;82(1):56–61. [PubMed] [Google Scholar]
  15. Pauwels S., Dockray G. J., Walker R., Marcus S. N-terminal tryptic fragment of big gastrin. Metabolism and failure to influence gastrin 17-evoked acid secretion in humans. Gastroenterology. 1984 Jan;86(1):86–92. [PubMed] [Google Scholar]
  16. Petersen B., Christiansen J., Rehfeld J. F. The N-terminal tridecapeptide fragment of gastrin-17 inhibits gastric acid secretion. Regul Pept. 1983 Dec;7(4):323–334. doi: 10.1016/0167-0115(83)90104-0. [DOI] [PubMed] [Google Scholar]
  17. Petersen B., Rehfeld J. F. The NH2-terminal tridecapeptide fragment of gastrin-17 in serum from duodenal ulcer patients. Scand J Gastroenterol. 1980;15(1):29–31. doi: 10.3109/00365528009181427. [DOI] [PubMed] [Google Scholar]
  18. Schrumpf E., Semb L. S., Vold H. Metabolic clearance and disappearance rates of synthetic human gastrin in man. Scand J Gastroenterol. 1973;8(8):731–734. [PubMed] [Google Scholar]
  19. Uvnäs-Wallensten K., Rehfeld J. F. Molecular forms of gastrin in antral mucosa, plasma and gastric juice during vagal stimulation of anesthetized cats. Acta Physiol Scand. 1976 Oct;98(2):217–226. doi: 10.1111/j.1748-1716.1976.tb00239.x. [DOI] [PubMed] [Google Scholar]
  20. Walsh J. H., Isenberg J. I., Ansfield J., Maxwell V. Clearance and acid-stimulating action of human big and little gastrins in duodenal ulcer subjects. J Clin Invest. 1976 May;57(5):1125–1131. doi: 10.1172/JCI108379. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES